Drugs / EG-101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07327255 | Jun 2026 → Mar 2027 expected | preeclampsia | Evergreen Therapeutics, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EG-101 | “Drug: EG-101 100 mg IVPB once (Level A)” NCT07327255 ↗ |
| Route | Intravenous | “EG-101 100 mg IVPB once (Level A)” NCT07327255 ↗ |